Details

Autor(en) / Beteiligte

• McLean, Huong Q.
• Thompson, Mark G.
• Sundaram, Maria E.
• Kieke, Burney A.
• Gaglani, Manjusha
• Murthy, Kempapura
• Piedra, Pedro A.
• Zimmerman, Richard K.
• Nowalk, Mary Patricia
• Raviotta, Jonathan M.
• Jackson, Michael L.
• Jackson, Lisa
• Ohmit, Suzanne E.
• Petrie, Joshua G.
• Monto, Arnold S.
• Meece, Jennifer K.
• Thaker, Swathi N.
• Clippard, Jessie R.
• Spencer, Sarah M.
• Fry, Alicia M.
• Belongia, Edward A.

Titel

Influenza Vaccine Effectiveness in the United States During 2012-2013: Variable Protection by Age and Virus Type

Ist Teil von

• The Journal of infectious diseases, 2015-05, Vol.211 (10), p.1529-1540

Ort / Verlag

United States: Oxford University Press

Erscheinungsjahr

2015

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Background. During the 2012-2013 influenza season, there was cocirculation of influenza A(H3N2) and 2 influenza lineage viruses in the United States. Methods. Patients with acute cough illness for ≤7 days were prospectively enrolled and had swab samples obtained at outpatient clinics in 5 states. Influenza vaccination dates were confirmed by medical records. The vaccine effectiveness (VE) was estimated as [100% × (1 - adjusted odds ratio)] for vaccination in cases versus test-negative controls. Results. Influenza was detected in 2307 of 6452 patients (36%); 1292 (56%) had influenza A(H3N2), 582 (25%) had influenza B/Yamagata, and 303 (13%) had influenza B/Victoria. VE was 49% (95% confidence interval [CI], 43%-55%) overall, 39% (95% CI, 29%-47%) against influenza A(H3N2), 66% (95% CI, 58%-73%) against influenza B/Yamagata (vaccine lineage), and 51% (95% CI, 36%-63%) against influenza B/Victoria. VE against influenza A(H3N2) was highest among persons aged 50-64 years (52%; 95% CI, 33%-65%) and persons aged 6 months-8 years (51%; 95% CI, 32%-64%) and lowest among persons aged ≥65 years (11%; 95% CI, -41% to 43%). In younger age groups, there was evidence of residual protection from receipt of the 2011-2012 vaccine 1 year earlier. Conclusions. The 2012-2013 vaccines were moderately effective in most age groups. Cross-lineage protection and residual effects from prior vaccination were observed and warrant further investigation.